Glottis neoplasm

Summary

Glottis neoplasm (MONDO:0002353) is a cancer and 2 clinical trials. A subtype of laryngeal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	glottis neoplasm
Mondo ID	MONDO:0002353
DOID	DOID:2597
NCIT	C4425
SNOMED CT	126693009
UMLS	C0345713
MedGen	138026
Anatomy (UBERON)	UBERON:0002486
Is cancer (heuristic)	yes

Also known as: glottis neoplasm · glottis neoplasm (disease) · glottis tumor · glottis tumour · neoplasm of glottis · neoplasm of the glottis · tumor of glottis · tumor of the glottis · tumour of glottis · tumour of the glottis

Disease family

This is a subtype of laryngeal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › laryngeal disorder › laryngeal neoplasm › glottis neoplasm

Related subtypes (5): subglottis neoplasm, larynx cancer, benign laryngeal neoplasm, supraglottis neoplasm, laryngeal neuroendocrine neoplasm

Subtypes (2): glottis cancer, benign neoplasm of glottis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03759431	PHASE2	ACTIVE_NOT_RECRUITING	Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
NCT04057209	Not specified	RECRUITING	VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer